| Document |
Document Title |
|
WO/2021/098703A1 |
Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds repre...
|
|
WO/2021/102115A1 |
The present disclosure provides processes for preparing an alpha-hydroxy ester by addition of a vinyl Grignard reagent to an oxalate ester and thiolation of the resulting double bond. Also provided are alpha-hydroxy esters and synthetic ...
|
|
WO/2021/092474A1 |
Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.
|
|
WO/2021/088756A1 |
The present invention discloses an oxime ether compound with a novel structure, wherein the structure is represented by general formula (I), and the definition of each substituent in the formula is described in the description. The compo...
|
|
WO/2021/082901A1 |
Provided are a phenylisoxazoline compound and use thereof. The phenylisoxazoline compound is represented by general formula (I). The compound of general formula (I) has good herbicidal activity, and can effectively control barnyard grass...
|
|
WO/2021/085991A1 |
The present disclosure pertains to a cinnamic amide derivative activating an FXR function, a pharmaceutical composition comprising an isomer, solvate, or pharmaceutically acceptable salt thereof, and a preparation method therefor.
|
|
WO/2021/083345A1 |
Disclosed in the present invention is a preparation method for a pyrazolopyrimidine compound. Also disclosed in the present invention is a preparation method for a compound of formula (I) and an intermediate compound thereof.
|
|
WO/2021/073643A1 |
The present application relates to the field of medicine, relates to drugs for treating non-alcoholic steatohepatitis, in particular, to linked cyclic compounds for treating non-alcoholic steatohepatitis, more in particular, to a compoun...
|
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2021/058754A1 |
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...
|
|
WO/2021/062199A1 |
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/050672A1 |
Described herein are compounds that are kinase inhibitors. The disclosed compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes including, making them useful for t...
|
|
WO/2021/047627A1 |
A compound as shown in formula (II) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound as an active ingredient, and use thereof in the preparation of medicaments for protein degradation.
|
|
WO/2021/050555A1 |
The present invention relates to compositions and methods for the treatment of disorders that lead to accumulation of oxalate, such as primary hyperoxaluria 1.
|
|
WO/2021/038501A1 |
The present invention discloses an isoxazoline compound of formula (I), wherein, R1, R2a, R2b, R2c, A, T and Z are as defined in the detailed description. The present invention further discloses methods for preparation of compounds of fo...
|
|
WO/2021/037156A1 |
Disclosed are a crystal of a carcinogenic fused kinase inhibitor and a preparation method therefor; also disclosed are applications of the crystal in preparing a medicament for treating tumor-related diseases.
|
|
WO/2021/033633A1 |
Provided is an organic nanoparticle production method that includes a step in which a mixture including beads having an average particle size of at least 0.15 mm and no more than a value (mm) calculated by the formula 1.07 - 0.11 × (out...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/018833A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/008485A1 |
Provided are isoxazoline derivatives and uses thereof in agriculture; in particular, provided a compound having formula (I), a stereoisomer, an N-oxide or a salt thereof, preparation methods thereof, and compositions containng these comp...
|
|
WO/2021/010492A1 |
The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is usefu...
|
|
WO/2021/000867A1 |
Disclosed are an isoxazoline compound and an application thereof. The structure of the compound is as shown in general formula (I). The definitions of substituents in the formula are described in the description. The description also dis...
|
|
WO/2021/000865A1 |
An isoxazoline compound, a preparation method therefor and an application thereof. The compound has a structured as represented by general formula I. Also provided is use of the compound represented by general formula I as an insecticide...
|
|
WO/2021/000684A1 |
Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R 1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole com...
|
|
WO/2021/000297A1 |
Disclosed herein relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R 1 are as defined herein. Disclosed herein also relates to compositions which comprise at least one dihydroisoxazole c...
|
|
WO/2020/262648A1 |
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/254492A1 |
The present application relates to the use of hydroxyisoxazolines and derivatives thereof as fungicides. It also relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof.
|
|
WO/2020/254489A1 |
The present application relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof. Formula (I)
|
|
WO/2020/257139A1 |
The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA recepto...
|
|
WO/2020/254490A1 |
The present invention relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof. Formula (I)
|
|
WO/2020/254554A1 |
This disclosure relates to an improved chemical process for making compounds of formula I which are CIC-1 chloride channel inhibitors using the compounds of formula II as starting material. (Formula I, II)
|
|
WO/2020/257138A1 |
The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhi...
|
|
WO/2020/254487A1 |
The present disclosure relates to the use of hydroxyisoxazolines and derivatives thereof as fungicides. It also relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof. Formula (I)
|
|
WO/2020/252353A1 |
These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions inclu...
|
|
WO/2020/251006A1 |
The present invention addresses the problem of providing a production method for a 4,5-dihydroisoxazole represented by formula (5), said production method being industrially desirable, economical, and environmentally friendly. The pres...
|
|
WO/2020/249760A1 |
The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly h...
|
|
WO/2020/247665A1 |
Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. I...
|
|
WO/2020/243423A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2020/242943A1 |
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments,...
|
|
WO/2020/240178A1 |
A compound, e.g. a diamine ligand, represented by the following general formula (1): (Formula (1)) wherein each * represents an asymmetric carbon atom; X represents a group selected from one of an ester (e.g. a t-butyl ester); a thioeste...
|
|
WO/2020/240392A1 |
The present invention discloses a process for the preparation of Pyroxasulfone of Formula (I) or salt thereof. Particularly, the present invention discloses an improved process for the preparation of hydroxycarbonimidic dibromide compoun...
|
|
WO/2020/233618A1 |
Provided in the present invention are inhibitors for programmed cell necrosis, a preparation method therefor and a use thereof. Specifically, provided in the present invention are a compound represented by formula I and a composition com...
|
|
WO/2020/227875A1 |
The present invention provides a high-purity thermostable crystal form of substituted 3-isoxazolidinone compound, preparation method therefor, and application thereof. The high-purity thermostable crystal form is prepared by a particular...
|
|
WO/2020/227168A1 |
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with th...
|
|
WO/2020/208307A1 |
The present invention relates to crystalline form 1 of 6-(3, 5-dimethylisoxazol-4-yl)-7- methoxy-3 -methyl- 1 -(pyridin-2-ylmethyl)quinolin-2( 1 H)-one (I) and to a method of manufacture thereof Compound (I) is a BET inhibitor useful in ...
|
|
WO/2020/200209A1 |
Provided are an aromatic amine compound and a use thereof in the preparation of AR and BRD4 dual inhibitors and regulators. Specifically provided is the compound shown in formula I, said compound having dual inhibitory effects on AR and ...
|
